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Sure Start in England
Abstract

In her Comment (Nov 8, p 1610) on our second phase of evaluation of Sure Start local programmes in
England, Penny Kane makes several points with which we could not agree more. Like her, we would have
much preferred to see a randomised controlled trial done, since this would have afforded much stronger causal
inferences than the quasi-experimental investigation we undertook. We also agree that the fact that we drew
on data collected by two different research teams raises questions about the confidence that can be placed in
conclusions drawn.
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Sure Start in England
In her Comment (Nov 8, p 1610)1
on our second phase of evaluation
of Sure Start local programmes in
England,2 Penny Kane makes several
points with which we could not
agree more. Like her, we would have
much preferred to see a randomised
controlled trial done, since this
would have aﬀorded much stronger
causal inferences than the quasiexperimental investigation we undertook. We also agree that the fact
that we drew on data collected by
two diﬀerent research teams raises
questions about the conﬁdence that
can be placed in conclusions drawn.
Indeed, these were points we made
in our original report.
We remain agnostic as to whether
the positive effects of Sure Start
local programmes we detected
were insufficient to be of policy
importance or should have emerged
on other child outcomes such as
verbal ability, especially in so short
a time frame (ie, when children are
3 years old). Open-minded scholars
can have honest disagreements on
this issue.
We are continuing to follow up the
children and families to determine
whether, at age 5 years, the eﬀects
detected at age 3 years have been
maintained, dissipated, or changed
in some manner. We look forward to
reporting on this matter in the nottoo-distant future.
We declare that we have no conﬂict of interest.
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The UK’s system of general practice,
based on the long-term registered
population, is one of the most popular,
successful, and eﬃcient ways of delivering primary health care. It allows
for continuity of care, a multidisciplinary approach, and a systematic
integration of individual and family
acute health care with risk management, preventive interventions, and
care of long-term disorders. How tragic
that the potential of this horizontal
approach, so often shown to be
successful, has been ignored by the
vertical approach in relation to health
care embodied in children’s centres
and the Sure Start programme.
I work in a large general-practice
team that includes doctors, nurses,
and child health visitors, in a health
centre owned by the National Health
Service. I walked 200 m down the
street to discover a children’s centre
under construction, of which none of
us was aware. Although the additional
support for families and children from
psychology to baby massage is very
welcome, it is no surprise that this
separate programme is associated
with lower child immunisation
rates.1,2 Immunisation normally takes
place in general practice, where Sure
Start has no structural input.
This has been a missed opportunity
for strengthening children’s services
through horizontal integration of
social services with primary health
care, and is ironic at a time when the
UK government has been promoting
polyclinics in the community.
Development is always needed. I hope
it is not too late to grow together.
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safety of the tested drugs were not
diﬀerent between patients with and
without diabetes. We recorded the
glycaemic and glycosylated haemoglobin values at baseline and during
the 3·9 years of average follow-up. As
for glitazones, their use is not extensive in Italy, but we did not speciﬁcally
record this treatment.
Christopher Florkowski and colleagues again bring up the hypothesis
that a reduction in coenzyme Q10
induced by statins might mask the
potential beneﬁts of these drugs in
patients with heart failure. Actually
the Q10 argument was usually a
safety concern, yet rosuvastatin
seemed to be safe in GISSI-HF as
well as in the CORONA trial.3 As for
eﬃcacy, although the possibility that
a potential beneﬁt from statins might
be concealed by a decrease in Q10
production cannot be ruled out, the
perspective of admistering two drugs,
one to counteract the negative eﬀect
of the other, to elderly patients with
heart failure, who are probably already
on multiple drugs, does not seem too
promising.
Vincenzo Solfrizzi and coauthors
seem to consider the GISSI-HF populations too heterogeneous, with frail
elderly patients being over-represented. However, in the GISSI-HF
population, two-thirds were of New
York Heart Association (NYHA) class
II and the remaining third were class III
patients with a mean age of 67 years
(the median age of patients with
chronic heart failure being around
75 years). Accordingly, the criticism
looks unfounded.
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